AFT new FDA approval could be a shot in the arm

AFT new FDA approval could be a shot in the arm
Analyst sentiment is positive after FDA approval of Maxigesic IV. (Image: Hyloris Pharmaceuticals)
Ben Moore
AFT Pharmaceuticals had a bump in share price on Wednesday morning following approval of its intravenous post-operative pain relief drug by the United States Food and Drug Administration.Following the announcement of the approval of Maxigesic IV, which came in overnight, the stock lifted 16 cents per share to $3.56 at the open on the New Zealand stock exchange (NZX), up from $3.40 at yesterday's close. It has since dipped to $3.50.AFT co-founder and managing director Hartley Atkinson said they were delighted to receive the second appro...

More Markets

Metroglass recap plan hands control to Amari Metals
Markets

Metroglass recap plan hands control to Amari Metals

An independent report said Metroglass was left with “no viable alternatives”.

Vital presses remaining shareholders to back takeover
Markets

Vital presses remaining shareholders to back takeover

Vital wants shareholders to accept “without delay”.

The problem with wet sock small caps
Markets

Eden Bradfield: The problem with wet sock small caps

Why are smaller firms better off as private companies?

Eden Bradfield 09 Aug 2025
Late selling drives NZ sharemarket down
Markets Market Close

Late selling drives NZ sharemarket down

There were 72 rises and 52 falls on the main board.

Jamie Gray 08 Aug 2025